I absolutely agree but, for completeness, it would be good to put it on the record that we do not hope to use the session to analyse one particular drug and the approval process for that individual drug. We are talking about futureproofing the system for all new drugs that might emerge, so we want to look at the nuts and bolts of the system to see, irrespective of whether a drug is approved, whether there is a way in which the timeframe of the process would allow us to make speedier decisions and bring more certainty to the process. That would be a useful evidence session.
It is. If I remember rightly—again, I am drawing on knowledge from one of the events that Nanette Milne sponsored in the Parliament—irrespective of the outcomes of IPTRs, some areas use far more than other areas. That information was available to us, Nanette. We may not be able to do this today, but I wonder whether we can work out two areas that we can contrast. We can consider why IPTRs are used fairly regularly in some parts of the country, but seldom in other parts. It might be quite useful to try to tease out the differences and the reasons for them.
I am sure that the inquiry will allow this to happen, but I want to consider how we quantify the health, social and community benefits from public money that is invested in community sport. I am not talking about anecdotal benefits, but outcomes that can be measured. I have previously told the committee that I have been to look at the football fans in training project at Celtic Park, and I believe that the University of Glasgow is monitoring how successful that project has been. I am not talking about a bid for one club over another—I think that Inverness Caledonian Thistle has just been given an award for its football fans in training programme. More important are the academic data that have been produced on what the benefits are. If public investment is involved, we want to be able to quantify the positive outcomes. I make the appeal that, when we finalise our witness panels, we should scratch beneath the surface of the anecdotal benefits of community sports. We all know that there are benefits, but quantifying them can be difficult. We should consider getting witnesses to the committee who have done work to quantify what those benefits are.
It sounds like a good idea. If we do not go for that chamber slot—although I think that we should—would there be an opportunity to debate the completed report at a later date? If we put recommendations in the report, we will want to debate them in the chamber and bring more focus to the Government’s response to them.
I agree with Fiona McLeod. It would be reasonable to slot in a focused session, perhaps before the parliamentary recess. The issue is just about timing. It would be good to find out what lessons have been learned. In any crisis, lessons will be learned. We need to disseminate best practice on resilience across health boards in case something similar happens again—heaven forfend. I agree with Fiona McLeod that we should contact NHS Lothian, or whomever we agree should come in, and say that we would like them to come before recess, but then wait to see what they say. I believe that they will be keen to come. Drew Smith has done the committee a service by raising the issue.
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.